HA Sustainable Infrastructure Capital, Inc. · NYSE:HASI
HA Sustainable Infrastructure Capital — FSD Pharma — Investor Presentation (December 2021)
20 slides from HA Sustainable Infrastructure Capital's investor presentation, December 2021
Slide 1: Helping restore our way of life
helping restore our WAY OF LIFE CSE: HUGE December 2021 NASDAQ: HUGE FRA: 0K9A
Slide 2: FSD Pharma Inc. Disclaimer
FSD Pharma Inc. Disclaimer IMPORTANT: You Must Read The Following Before Continuing The information contained in this presentation has been prepared by FSD Pharma Inc. (“FSD” or “the Company”) and contains information pertaining to the business, operations, assets and prospects of the Company. The i
Slide 3: Forward-Looking Statements
Forward-Looking Statements This document contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United Sta
Slide 4: Pipeline of Clinical Candidates Addressing Multibillion-Dollar Markets
Pipeline of Clinical Candidates Addressing Multibillion-Dollar Markets FSD Pharma is focused on innovative biotech space to bring advanced neurodegenerative and mental health treatments to market. We are rooted in world-class science and research-based advancements. 1 2 3 Lucid-PSYCH Lucid-MS FSD-PE
Slide 5: Expert Research and Clinical Team
Expert Research and Clinical Team • Professor, Leslie Dan Faculty of Pharmacy, University of Toronto • Senior Scientist, Krembil Research Institute, University Health Network Lakshmi P. Kotra, BPharm(Hons), PhD • Expert in drug discovery and development CEO of Lucid • Serial entrepreneur and co-foun
Slide 6: The Psychedelics Market Opportunity (Lucid-PSYCH)
The Psychedelics Market Opportunity (Lucid-PSYCH) LUCID-PSYCH Growing body of research suggests Psychedelics have the potential to treat a variety of neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD, and anxiety • FDA approval of SPRAVATO® (esketamine) for treatm
Slide 7: Major Depressive Disorder (MDD) (Lucid-PSYCH)
Major Depressive Disorder (MDD) (Lucid-PSYCH) LUCID-PSYCH MDD Overview • Characterized by depressed mood or loss of interest in pleasure for at least 2 weeks The global anxiety disorders and • Periods of remission and relapse over a lifetime depression treatment market size was • 300 million people
Slide 8: FSD Pharma Differentiation (Lucid-PSYCH)
FSD Pharma Differentiation (Lucid-PSYCH) LUCID-PSYCH Lucid-PSYCH Psychedelics Can Be Highly Effective Development Stage Preclinical Depression Decreases After Psilocybin Treatment Mental health and Target Condition neurodegenerative conditions Severe depression Proprietary molecules Yes Moderate dep
Slide 9: Multiple Sclerosis (Lucid-MS)
Multiple Sclerosis (Lucid-MS) MS Overview1 LUCID-MS • A chronic inflammatory and degenerative Est. Diagnosed MS Patients by Region disorder of the central nervous system 600,000 543,862 • Unpredictable pattern of symptoms (tingling, 511,855 vision problems, mobility issues, etc.) has to do with whic
Slide 10: Lucid-MS: Disease Modifying Agent Enabling Remyelination
Lucid-MS: Disease Modifying Agent Demyelination Enabling Remyelination LUCID-MS Myelin (Neuronal Insulator) is Attacked by MS Patients’ Immune System Goal = Remyelination 10
Slide 11: Lucid-MS: Disease Modifying Agent Enabling Remyelination
Lucid-MS: Disease Modifying Agent Enabling Remyelination LUCID-MS • Lucid-MS has over 11 years of R&D and FSD owns worldwide exclusive rights for the family of compounds for development and marketing • Excellent efficacy in various preclinical animal models • Treatment accelerates functional recover
Slide 12: FSD-PEA: Ultra Micro-PEA
FSD-PEA: Ultra Micro-PEA An anti-inflammatory agent FSD-PEA • A well-researched compound in preclinical and clinical studies • Addresses large markets with growth opportunities in opioid-sparing indications (pain, post-surgical pain, morphine tolerance etc.), endometriosis, osteoarthritis, fibromyal
Slide 13: FSD-PEA: Ultra Micro-PEA
FSD-PEA: Ultra Micro-PEA An anti-inflammatory agent FSD-PEA • An endogenous compound, and a key regulator of endocannabinoid system in inflammation • PEA activates GPR55 and PPAR-α receptors, leads to increased expression of CB2 receptors • PEA increases the endogenous levels of 2-AG and AEA, which
Slide 14: FSD-PEA: Ultra Micro-PEA
FSD-PEA: Ultra Micro-PEA An anti-inflammatory agent FSD-PEA • FSD-PEA is a proprietary formulation, enhances its bioavailability and efficacy • FSD Holds exclusive worldwide licensing rights (except Italy & Spain) to FSD-PEA • Successfully completed Phase-1 first-in- human safety and tolerability tr
Slide 15: Strong Financial Position
Strong Financial Position Cash Position: USD $39.3M1 Capitalization Table: Outstanding1 Class A Shares 72 Class B Shares 40,557,896 Options 3,314,810 Warrants 6,749,109 1) As of September 30, 2021 15
Slide 16: Pipeline
Pipeline In vivo IND Enabling Idea/Target Lead Phase 1 Phase 2 Phase 3 Launch PoC Studies Lucid-PSYCH Anticipated Major Depression Disorder 4th Quarter 2022 Lucid-MS Anticipated Multiple sclerosis 4th Quarter 2022 FSD-PEA Anticipated Inflammatory disorders 2nd Quarter 2022 16
Slide 17: Comparable Companies with Similar Drug Candidate Targets
Comparable Companies with Similar Drug Candidate Targets Company Symbol Market Cap* Psychedelics Multiple Sclerosis PEA Atai Life Sciences ATAI $2.1B COMPASS Pathways CMPS $1.25B Eliem Therapeutics ELYM $520.1M MediciNova MNOV $179.7M Longboard Pharmaceuticals LBPH $155.8M FSD Pharma HUGE $59.6M * A
Slide 18: Experienced Executive Leadership
Experienced Executive Leadership Management Team Board of Directors Anthony Durkacz Zeeshan Saeed Anthony Durkacz Nathan Coyle, CPA Donal Carroll Executive Co-Chairman, Chief Financial Officer Co-Founder & Interim CEO Larry Latowski Adnan Bashir Fernando Cugliari Nitin Kaushal Zeeshan Saeed Lakshmi
Slide 19: Investment Highlights
Investment Highlights Focused on Positioned for Growth Well-Capitalized Advancing Neuro and Strategically advancing drug Ability to pursue and integrate Anti-inflammatory Assets pipeline focused on novel and acquisitions that present unique treatments – unmet compelling opportunities • Lucid-PSYCH n
Slide 20: Contacts
Contacts Investor Relations Stephen Kilmer Email: skilmer@fsdpharma.com Corporate Anthony Durkacz Interim CEO Email: adurkacz@fsdpharma.com Zeeshan Saeed Founder, President and Executive Co-Chairman Email: zsaeed@fsdpharma.com www.fsdpharma.com